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Anesthetic Pathway / Mechanism 
 For conformation to occur between an anesthetic 
agent and its target, it would be expected that the agent 
would be highly specific. But the broad arrays of such 
agents, with their varied structural and chemical composi-
tions seem to belie such a nature. Nevertheless, all general 
anesthetics work through either of two primary transmis-
sion mechanisms: NMDA (N-methyl-D-aspartate) receptor 
antagonists or GABA mimetic receptors (gamma-
aminobutyric acid). 
 GABA receptors, a type of ligand-gated ion chan-
nel, are the main inhibitory neurotransmitter in the central 
nervous system (Colquhoun et al. 2004).  The sedative 
effect of the GABAa agonists is caused by the inhibition of 
firing new action potentials. When molecules bind extra-
cellularly, a selective Cl ion pore is opened. This increased 
accessibility of the Cl ion drives it towards -65mV, a mem-
brane potential at which there is no overall change in the 
ion concentration on either side of the membrane, a situa-
tion called reversal potential. 
 NMDA receptor antagonists block the glutamate 
and glycine from binding to the receptor, blocking signal 
transmission between the spinal cord and the brain (Olney 
et al. 1991). NMDA receptors are important in the function 
of neuronal migration and differentiation, synaptic plastici-
ty, and in promoting learning and memory. Glutamate re-
ceptors are the most common excitatory neurotransmitter 
found in mammals. NMDA glutamate receptor antagonists 
include ketamine and nitrous oxide, both widely used in 
pediatric anesthesia. The collective effect of GABAa ago-
nists and NMDA antagonists is to block synaptic transmis-
sions from occurring between neurons and the spinal cord. 
Methods 
 Data presented in this paper was mined from case 
studies, review articles, online sources, and scientific jour-
nals using search engines of the Touro College Library da-
tabase, EBSCO, Pubmed, and Google Scholar. 
Discussion 
Effects on lower mammals 
Deleterious effects of anesthetics on developing neural 
cells was first observed in extensive exposure of rat pups 
on postnatal days 0,3,7, and 21 to Dizocilpine [(+)MK 801], 
an NMDA receptor antagonist (Ikonomidou et al. 1999). 
NMDA receptor activation promotes survival of their re-
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spective cells. Even brief periods of inhibition were shown 
to cause brain-wide apoptosis. Rats were injected variously 
with .5mg, .75, and 1mg per kg of body weight and apopto-
sis was measured after 24 hours using terminal deoxynu-
cleotidyl transferase dUTP nick end labeling (TUNEL). 
TUNEL is a common technique for identifying DNA frag-
mentation representative of apoptotic signaling cascades 
by marking the terminal end of nucleic acids. 
 Pervasive apoptosis was perceived throughout the 
brain including within the hippocampus, dentate gyrus, 
thalamus, hypothalamus, frontal cortex, parietal cortex, 
cingulate cortex, and retrosplenial cortex, as evidenced by 
decreased cell density. The apoptotic effect was most pro-
nounced in 7 day old rats when expression of NMDA re-
ceptors peak. The neural deletion was commensurate with 
the influence of both dosage and time factors (Figure 1A). 
The enantiomer, (-)MK 801, known to be less effective in 
its ability to inhibit NMDA receptor signal transmission, 
was also tested. The effects of (-)MK 801 remained negligi-
ble relative to the vehicle treated rats (the control; rats just 
given the solvent without the active ingredient, MK801) up 
to a dose of 1.0 mg/kg. Electron microscopy demonstrated 
that these degenerate cells showed no physiological or 
ultrastructural distinction from corresponding apoptotic 
cells. 
 
Figure 1: Part (A) shows the detrimental effect of MK 801 is pro-
portional to the dosage. Solid circles denote (+)MK 801; Empty 
circles represent  (-)MK 801. The dashed line represents vehicle 
treated rats. Part (B) demonstrates a relationship between the 
degeneration and the time of exposure. Only (+)MK 801 was 
used. The dashed line shows the level of spontaneous apopto-
sis. (Source: Ikonomidou et al.1999) 
Embryonic rats in utero were also given 0.5mg (+)MK 801 
at embryonic days 17, 19, and 21 for 8 or 16 hours, and 
were examined after 24 hours. Significant apoptosis oc-
curred in the embryonic 21 day old rats in the dentate gy-
rus, hippocampus and hypothalamus. Embryonic day 19 
rats showed some modest apoptosis while embryonic day 
17 rats showed no sign of apoptosis. 
 At certain points in the postnatal period rats were 
more vulnerable to neural degeneration than during the 
fetal period. Increased vulnerability in the postnatal period 
may result from the subunit composition of the NMDA re-
ceptor which is modified in the transition from the embry-
onic to the postnatal stage.  Higher expression of NMDA 
receptors at certain periods would make the cells more 
vulnerable to the NMDA antagonist. 
 Most concerning was that ketamine, a common 
pediatric anesthetic, was also shown to cause neuroapop-
tosis in the developing rat brain.  Humans are more devel-
opmentally advanced than rats and these results are diffi-
cult to extrapolate, but these findings suggest a period of 
susceptibility in humans during the corresponding period. 
This time frame is controversial, and an early postnatal 
study in rats may compare to late gestation or the new-
born stage. Perhaps the danger exists throughout the cor-
responding brain growth spurt period (synaptogenesis) 
which lasts from mid-gestation to several years after birth. 
 GAs were also shown to have a time dependent 
effect with apoptosis shown to continually accentuate 
when rats were given 0.5mg/kg and were killed variously at 
4,8,12,16,24, and 48 hours after being subjected. With the 
passage of just 4 hours apoptotic effects were apparent. A 
peak effect was reached after 24 hours while after 48 
hours the effects mostly subsided (Figure 1B). 
Apoptosis - Essential for Life 
 During normal development of the central nerv-
ous system apoptosis plays an integral part in the devel-
opment. Signals that proliferate or restrain the apoptotic 
program using a precise biochemically guided system 
controls the number of cells extant and are important in 
shaping controlling and establishing the development of 
cells. When apoptotic caspases were eliminated to block 




increased subpopulations in the brain occurred and in 
some cases resulted in lethality. Apoptosis further aids in 
sexual differentiation, development of olfactory and ther-
moregulatory systems, and processing of pheromones 
(Broad et al. 2009). While a moderate amount of neural 
cells undergo apoptosis to support healthy development, 
the number of cells undergoing apoptosis in regions 
throughout the brain upon administration of general anes-
thetics was excessive. 
 Do disturbances in other major excitatory trans-
mitter systems of the brain also cause widespread  
neuroapoptosis? No, it is not apparent in antagonists of 
excitatory pathways such as the muscarinic or non-NMDA 
glutamate antagonists. Nor does it occur in agonists of the 
inhibitory dopaminergic system. Only with the use of 
NMDA antagonists and GABAa agonists is widespread 
apoptosis apparent (Ikonomidou et al. 1999). Because of 
these discoveries, researchers set out to discover the 
effects of GABAa mimetics, NMDA antagonists, and the 
combined neurotoxic effects of the two. 
Permanent Effects on Intelligence 
 Even presuming robust apoptotic effects upon sub-
jection to anesthetics, what practical significance would it 
have?  Jevtovic-Todorovic et al. (2003) showed that  
exposure of developing rodents to anesthetics results in a 
decline in brain density leading to a long-term decline in 
cognitive function. Seven day old rats were anesthetized 
for 6 hours with N2O, isoflurane (ISO), and midazolam 
(triple anesthetic cocktail). They were put in the Morris  
Water maze and trained to swim to an observable stand. 
Their performance concerning path length and vigor in the 
Morris Water maze was on a par with that of the  
control.  When the stand was submerged in the 
same location, the triple anesthetic cocktail rats 
showed substantial learning deficits in the middle 
trials, although they performed at the same level as 
the controls by the test’s conclusion. When retested 
as adults, their lower memory capacity was evident 
when they spent less time searching for the  
submerged stands in the area of the pool in which it 
was had formerly been raised. Control rats spent 
more time searching the appropriate pool area for the 
stand’s location. Spatial memory was shown to be im-
paired in the anesthetic cocktail rats by use of a radial arm 
maze, with a significant learning deficit as compared to the  
performance of the control. 
 Ikonomidou et al. (1999) learned that NMDA  
receptor antagonists can cause apoptosis. Wang et al. 
(2012) however contends that rats subjected to a dosage 
commonly used in clinical settings [NMDA receptor antago-
nist N2O (70%), or to the GABAa agonists ISO (1%)] showed 
no significant measure of apoptosis upon harvest and 
TUNEL examination after 6 hours. Rather, they needed to 
be subjected to prolonged and substantial doses of the 
NMDA receptor antagonist N20 or ISO for any measurable 
damage (Figure 2). 
 Separate administration did not cause significant 
apoptosis, but when administered concurrently, apoptotic 
levels were accentuated. While gene expression was  
altered when N2O and ISO was delivered independently 
the pathways of these genes are not closely associated 
with neurons, suggesting that cascades are inducing apop-
tosis rather than the anesthetic doing so directly. This pro-
vides hope to researchers. If the anesthetic itself does not 
directly cause the damage but instead generates a cascade 
to do so, scientists may be able to determine the point at 
which the damage occurs. A drug can then be developed 
to act in concert with the anesthetic and inhibit propaga-
tion of the damaging pathway. Accordingly, pediatric sur-
geons can continue to benefit from the sedative effects 
without concern for the health of the developing brain. 
 
Figure 2. The apoptotic damage in the ISO + N2O group relative 
to the control is apparent (Source: Wang et al. 2012) 
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Widespread Effects Observed 
 How serious are the effects generated by  
neuroapotosis? Huang et al. (2012) proposed that keta-
mine causes permanent learning and memory impairment. 
Postnatal day 7 rats were given doses of 25, 50, and 75 
mg/kg of ketamine for 3 days. At two months old, the 
group subjected to 75 mg/kg had a diminished capacity for 
memory and learning, as measured by the Morris water 
maze. Behavioral issues were observed as well. These 
effects were not apparent in the groups exposed to the 
smaller dosages. 
 Groups of rats were given the same treatment as 
described previously but dispatched after 3 days. TUNEL-
stained hippocampal neurons were compared between the 
hippocampal sub-regions cornu ammonis 1 (CA1), CA2, and 
CA3, and the dentate gyrus in rat pups. Groups subject to 
lower doses of 25or  50 mg/kg did not have higher rates of 
apoptosis while a group subjected to 75 mg/kg showed 
significant apoptosis in these regions. Protein expression of 
PKCγ, ERK1/2 and Bcl-2 in the hippocampus was measured 
by western blot. The greater dose of ketamine inhibited p-
PKC, p-ERK1/2 and Bcl-2 manifestation but not that of t-
PKC or t-ERK. These findings corroborate the position that 
the malign effects of ketamine are associated with p-PKC, p
-ERK1/2 and Bcl-2 expression, which in turn is related to 
persistent destructive cognitive effects. 
 Dikranian et al. (2001) suggested perhaps scien-
tists were mistaken in comparing neuronal cells believed to 
be undergoing apoptosis to non-neuronal cells. Maybe the 
detailed biological structure of a neuronal cell undergoing 
apoptosis would have a different ultrastructure than a cor-
responding cell in the rest of body. NMDA antagonists, and 
GABAa agonists were used to effect neuroapoptosis and 
the cellular ultrastructure of apoptotic cells was compared 
to that of a physiologically dying cell as it occurs naturally 
in the brain. It was verified to have similar properties to 
that set forth by the Kerr/ Wyllie team, the scientists who 
originally discovered and formulated the word apoptosis 
and classified the structure and formation of such a cell. 
Apoptosis Seen in Higher Primates 
 Perhaps only such an effect is observed in rats but 
higher non-human primates such as the monkey would be 
impervious to their affects. Zou et al. (2009) demonstrated 
this was not so. However, in contrast with the earlier rat 
studies, the primate monkeys needed to be overwhelmed 
by a high dosage of ketamine (20 mg/kg) for degeneration 
to occur. An initial intramuscular injection of 20 mg/kg was 
followed by continuous intravenous administration of  
20-50 mg/kg h for 3, 9, or 24 hours. The monkeys were  
dispatched after a 6 hour period to allow the anesthetics to 
take effect. Ketamine was confirmed with liquid  
chromatography and mass spectrometry. Brain slices of 40 
micrometers were prepared using a microtome and a  
polyclonal antibody that detects cleaved caspase-3, an 
effector of apoptosis. Out of all sections of the brain- the 
hippocampus, amygdala, cerebellum, cerebrum, thalamus, 
and striatum, apoptosis was concentrated mainly in the 
frontal cortex. 
 How long does a monkey need be exposed to  
ketamine for neurodegeneration to occur? Although three 
hours did not seem to cause neuoroapoptosis, exposure 
for more than nine hours did, while exposure for twenty-
four hours resulted in long term cognitive deficits (Figure 
3). Most welcome is the knowledge that the 3 hour period 
did not cause significant apoptosis, as this is the time 
frame for an average surgery. 
Figure 3. The effect of Ketamine over time. Note the insignifi-
















 Prolonged subjection to a high dosage of ketamine 
in postnatal day 3 perinatal rhesus monkeys for 24 h, with 
1, 10, or 20 µM of ketamine, an NMDA antagonist, caused 
neurodegeneration in the frontal cortical area (Wang et al. 
2006). Significant change in mitochondrial metabolism, 
DNA factionalism, and the release of lactate dehydrogen-
ase were also observed. These phenomena are all  
characteristic of apoptosis. 
 Even when ISO or ketamine was administered to 6 
day old rhesus monkeys for just 5 hours to maintain a light 
surgical plane and all physiological parameters were con-
trolled as they would be for a neonate patient, neuro-
degeneration ensued (Brambrink et al. 2010). Pronounced 
apoptotic neurodegeneration was especially apparent 
among the immature oligodendrocyte glial cells partici-
pating in myelination as well as neurons. ISO, a widely used 
anesthetic for maintaining a prolonged stable surgical 
plane, was shown to cause approximately 4 times more 
degeneration than ketamine. 
 Other studies discussed which regions of the brain 
were affected but Creeley et al. (2013) pinpoints the spe-
cific cells - neurons and oligodendrocytes just beginning to 
myellinate their axons - that were deleted. In this experi-
ment, 120 day old fetuses of rhesus monkeys, (comparable 
to a late third trimester human fetus) and 6 day old neo-
nates (similar to the 4-6 month old human brain) were 
subjected to propofol for 5 hours. A pronounced effect was 
detected in the subcortical and caudal areas in the fetus. 
The neonates caudal brain regions were affected less and 
neurocortical regional damage formed distinct laminar 
patterns. 
 Sun et al. (2012) showed that even adolescent 
monkeys, when administered ketamine regularly, devel-
oped permanent damage. This was evident from the apop-
totic effectors present in the prefrontal cortex. Macaque 
monkeys demonstrated abnormal behavior in their walk, 
jump, climb, and general movements. The damage ap-
peared permanent in the 6 month treated monkeys, while 
1 month treatment and control monkeys had no such dis-
play upon TUNEL testing. 
Can These Results be Extrapolated to Humans? 
 What can be done to determine definitively if this 
issue applies to the human fetus and neonates? How can 
such studies be done non-invasively in humans? While 
studies can be done retrospectively on humans who have 
already undergone treatment based on the incidence and 
statistical distribution of apoptotic neurodegeneration, 
there are many confounding factors such as the dosage 
amount and duration, acid-base disturbances, hypoxia, 
starvation, route of administration, developmental period, 
and the subtype receptors activated. There are many co-
factors present in humans absent in animals. To further 
muddle the matter, pediatric patients typically are adminis-
tered a combination of anesthetic agents such as benzodi-
azepines and/or anticholinergics, possibly reducing the 
amount of ketamine needed to maintain a surgical plane. 
Due to all these confounding factors, it is not clear if re-
sults from these studies can be extrapolated to humans. 
Perhaps if the epidemiological studies were well-
constructed and accounted for various variables by setting 
up groups of similar circumstances and arrange for a con-
trol for each group, it would aid in determining whether 
the human brain is vulnerable to apoptotic devastation by 
anesthetics. Or, methods can be developed for noninvasive 
techniques to determine if in vivo neurodegeneration 
takes place in the developing brain. 
Anesthetics - Similar to Ethanol? 
 Because of the similarities in the molecular path-
ways of intoxication and general anesthetic agents-ethanol 
is both an NMDA antagonist and a GABA agonist- 
Ikonomidou et al. (2000) suspected that that studies on 
the affects of ethanol on fetuses would be applicable to 
general anesthetics. Seven day old rats were given 2.5 g/Kg 
of 20% ethanol in saline, and compared to the control only 
given saline. TUNEL and silver staining showed only modest 
physiological cell death in the control while the subject 
group showed condensed pervasive sections of degenera-
tion. Creeley et al. (2013) presented the same affect on 
neurons and oligondrocytes in the fetal macaque brain. 
 Ethanol has a debilitating effect at the molecular 
level. Above a 12 mol % (30.5 v/v %) threshold, desorption 
results from breaks in the lipid-water interface of the bi-
membrane, some of the lipid fragments amalgamate with-
in the cell (Gurtovenko, Anwar, 2009). At the same time, 
components of the inner and outer leaflets of the lipid bi-
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Figure 3. The effect of Ketamine over time. Note the insignifi-
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monkeys demonstrated abnormal behavior in their walk, 
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Can These Results be Extrapolated to Humans? 
 What can be done to determine definitively if this 
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membrane, some of the lipid fragments amalgamate with-
in the cell (Gurtovenko, Anwar, 2009). At the same time, 
components of the inner and outer leaflets of the lipid bi-
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layer substitute one another’s position, permanently up-
setting the membrane structure. And this suggests that 
anesthetics may cause neurological damage just as ethanol 
causes developmental neurological damage to fetuses 
(fetal alcohol syndrome). Neurobehavioral deficiencies 
perceived to persist into adulthood include psychosis, hy-
peractivity, learning disabilities, and depression. 
Anesthetics’ Affects Persist into Maturity 
 Wilder et al. (2009), in a population based cohort 
study demonstrated retrospectively how children under 4 
years of age subjected to an incidence of anesthesia were 
unlikely to be affected. However, 2 or more periods of gen-
eral anesthetic application revealed a cognitive deficit as 
revealed by inferior scores on IQ and standardized achieve-
ment tests. Learning disabilities as characterized by poor 
math, reading and writing skills were apparent and they 
lagged continually further behind their peers as they ad-
vanced through school. By 19 years of age, 35% had a 
learning disability, representing a 15% rise against the gen-
eral population (Figure 4). Because of the controversy re-
garding how to relate the vulnerable developmental stage 
of animals to their corresponding human stage, the experi-
ment was repeated for children subjected to anesthesia for 
two or more instances. Similar results were generated. It is 
not clear if the anesthetics themselves or other factors 
were the cause. 
 
Figure 4: A population based cohort study demonstrating the 
long-term affect of multiple anesthetic incidence. (Source: Wil-
der et al. 2009) 
 
 But even if anesthetics are shown to definitively 
cause neurodegeneration, clinical medicine is not much 
further advanced. How can children who need surgery 
safely receive treatment? Anesthetic application to chil-
dren during surgery cannot simply be abandoned; its use 
prevents neurotoxicity from developing in the brain as well 
as the harmful effects of stress, anxiety and chronic pain 
disorders. Exposure to prolonged or repeated painful stim-
uli lowers the threshold of pain processing, and alters de-
velopment of the brain, cognitive functioning, and behav-
ior. Moreover, surgical patients who were not adminis-
tered anesthetics exhibited the very same pervasive neuro-
degeneration; nothing was gained by avoiding it. Anes-
thetic treatment resulted in attenuating the pain and pro-
tecting the developing brain. (Anand et al. 2004). Anes-
thetics also protect the brain from damage by preventing 
hypoxic and ischemic incidents, allowing the necessary ox-
ygen-carrying blood flow to continue to nurture the brain. 
Apoptotic Mechanism 
 A possible mechanism for GA induced neuroapop-
tosis is via the mitochondrial pathway (Figure 5). Molecular 
stimulation prompts association of Bcl-2 with mitochondri-
al Bcl-2, leading to the release of cytochrome c. Cyto-
chrome c in turn binds Apaf-1, effecting a change in its 
conformation. Apaf-1 association with procrease-9 allo-
sterically activates it, in turn stimulating procaspase-3 and 
procaspase-7. Perhaps a cascade induced by GAs cause the 
mitochondria to release more cytochrome c, leading to 
activation of more caspases. Sanchez et al. (2011) demon-
strated support for the theory of GAs affecting mitochon-
dria when he discovered that long term use of GAs com-
promised its structure and function as well as lingering dys-
function in inhibitory synapses in neural signaling. 
 
Figure 5 : (Printed on next page) A schematic summary of the 
apoptotic pathway. A stimulant triggers association of Bcl-2 with 
mitochondrial Bcl-2. The ensuing series of reactions activates 
caspases.  (Source: Kalantri 2010) 
 Alternatively, Kuwana and Newmeyer (2003) sug-
gests that GAs spur a release of a large concentration of Cl
(2+) from the ER lumen which can in turn lead to an in-




swells and the external membrane may burst. The cyto-
chrome c will then disperse throughout the cell and the 
apoptotic cascade will begin. Bcl-2 can bring about apopto-
sis by controlling the release of Ca(2+), thereby regulating 




Possible Protection Against Apoptosis 
 A viable alternative to GAs must be developed or 
the underlying mechanisms better studied and understood 
so as to address the specific toxic pathway. When ISO and 
N2O were administered together, differential gene expres-
sion was observed in 45 pathways related to the brain, 
highlighting the difficulties researchers have in trying to 
pinpoint the exact pathway by which the apoptotic dam-
age is caused and developing a drug to neutralize its 
affects (Wang et al. 2012). 
 Once the exact apoptotic pathway is determined, 
drugs can be developed to act in concert with the anes-
thetic to prevent the apoptotic cascade while maintaining 
the benefits of a sedative effect. Progress in labs has al-
ready been made in identifying a possible “antidote,” L-
carnitine. L- carnitine is an amino protein that supports 
oxidation of fatty acids and is  essential in skeletal muscle 
metabolism. L-carnitine, when administered concurrent 
with GAs, significantly minimized the damage even for long 
periods under high dosages (Zou et al. 2008). 
 Di Marzio et al. (1997) reports that sphingolipids 
play a key role in apoptosis; Apoptosis may be arrested by 
inhibition of a sphingolipid activation cascade. L-carnitine 
in AIDS patients blocked sphingomyelinase, thus pre-
venting sphingomyelin breakdown into phosphocholine 
and ceramide, an intracellular apoptotic effecting mole-
cule. Ceramide exists in the mitochondrial pathway. When 
high levels are present, the respiratory chain is prevented 
and cytochrome c is released (Ghafourifar et al. 1999). 
 Mechanisms in neuropathic diseases also lead to 
initiation of the apoptotic cascade with cytochrome c  
released into the cytoplasm (Di Cesare Mannell et al. 
2007). Treatment of rats with acetyl-L-carnitine reduced 
the amount of cytochrome c present in the cytosol and  
suppressed the apoptotic pathway. Unfortunately, L-
carnitine, when tested, did not provide successful  
protection. Acetyl-L-carnitine also reduced the number of 
chromatin undergoing the irreversible condensation of 
chromatin characteristic of apoptotic cells (karyopyknosis). 
 While the exact apoptotic effecting pathway of 
GAs is uncertain, it is probable that it is related to both 
sphingomyelinase and the release of cytochrome c into the 
cytoplasm. Consequently, it is likely that both L-carnitine 
and acetyl-L-carnitine would aid in preventing apoptosis. It 
is premature to declare whether one would be more suc-
cessful than the other in preventing neuroapoptosis while 
the basic pathways GAs trigger remain a mystery. Perhaps  
L-carnitine and acetyl-L-carnitine’s shielding capacity is  
applicable to only specific mechanisms initiated by a  
specific anesthetic or a specific form of the anesthetic’s 
administration. 
 The X-chromosome linked inhibitor of apoptosis 
protein (XIAP) acts as an important factor in the apoptotic 
pathway, inhibiting apoptosis by blocking the activity of 
caspase-3.  When the GA sevuflorane was delivered to lung 
carcinoma cells for up to 6 hours, apoptosis resulted,  
blocking cell proliferation (Liang et al. 2011). Researchers 
observed down-regulation of XIAP expression while caspa-
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se-3 levels rose. But administration of Acetyl-L-carnitine 
was shown to parallel a reduction of karyopyknosis,  
suggesting the induction of XIAP to block this occurrence 
(Di Cesare Mannell et al. 2007). 
Conclusion 
 While recent studies of rodents and primates  
suggest that GAs may cause apoptosis in the developing 
brain by its dual mechanism as an NMDA antagonist and 
GABAa agonist, whether this applies to the developing  
human brain remains inconclusive. Better constructed  
epidemiological studies would probably be the best route 
to determine unequivocally if the developing human brain 
is vulnerable. Should it prove to be vulnerable, protection 
in the form of L-carnitine and Acetyl-L-carnitine may be 
used to neutralize the malevolent affects in future pediat-
ric anesthesiology. 
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